Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-11-17 00:00:00 ET · period of report 2022-11-15 · accession 0001799191-22-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-17 | 2022-11-15 | STLN | Virnich Daniel | Pres | D - Sale to Iss | $2.03 | -3,767 | 233.5K | -2% | -$7,647 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-15 | D | D | 3,767 | $2.03 | 233,484 | D | — | — | (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |